RecruitingPhase 2NCT03875378

Transdermal Estrogen in Women With Anorexia Nervosa

Transdermal Estrogen for the Treatment of Bone Loss in Women With Anorexia Nervosa


Sponsor

Pouneh K. Fazeli, MD

Enrollment

66 participants

Start Date

Aug 28, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

Randomized, placebo-controlled study investigating the use of physiologic, transdermal estrogen for low bone mass in adult women with anorexia nervosa.


Eligibility

Sex: FEMALEMin Age: 19 YearsMax Age: 45 Years

Inclusion Criteria6

  • Female
  • 19-45 years of age
  • DSM-5 psychiatric criteria for anorexia nervosa
  • <85% of ideal body weight as defined by the 1983 Metropolitan Life Insurance Height and Weight Tables
  • Amenorrhea
  • T-score of < -1.0 at spine or hip

Exclusion Criteria15

  • Diseases known to affect bone metabolism, including untreated thyroid dysfunction, vitamin D deficiency, Cushing's syndrome, diabetes mellitus or renal insufficiency (eGFR < 60)
  • Personal history of venous or arterial clot
  • History of stroke or myocardial infarction
  • History of hypercoagulable disorder
  • Personal history or history of a first-degree relative with breast cancer
  • History of hereditary angioedema
  • Any medication known to affect bone metabolism, including systemic glucocorticoids within three months of the baseline visit, depot medroxyprogesterone within 6 months of the baseline visit, oral bisphosphonates within one year of the baseline visit or IV bisphosphonates within three years of the baseline visit
  • Bone fracture within the prior 12 months
  • Serum potassium < 3.0 meq/L, serum ALT > 3 times the upper limit of normal or Hemoglobin < 10 g/dL
  • Fasting serum triglyceride level > 150 mg/dL
  • Pregnant or breastfeeding (or desiring pregnancy within the next 18 months)
  • Active substance abuse
  • Elevated PTH level
  • 25-OH vitamin D level < 20 ng/mL
  • Low phosphorus level

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTransdermal estrogen

Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) weekly patch

DRUGPlacebos

Placebo weekly patch


Locations(1)

University of Pittsburgh School of Medicine

Pittsburgh, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03875378


Related Trials